Resources Repository
-
DataPublication 2023Trends in Maternal Mortality 2000 to 2020
This report presents global, regional, and country-level estimates and trends for maternal mortality between 2000 …
This report presents global, regional, and country-level estimates and trends for maternal mortality between 2000 and 2020 produced by the United Nations Maternal Mortality Estimation Inter-Agency Group (MMEIG).* The estimates are intended to inform progress in maternal mortality to support national efforts to meet Sustainable Development Goal (SDG) target 3.1, to reduce maternal mortality to less than 70 maternal deaths per 100,000 live births by 2030. The report is accompanied by a set of country…
Maternal/Reproductive Health | Health Outcomes | Evidence Synthesis | Mathematical Models | Health/Medicine | Global -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Policy/Regulation | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Policy/Regulation | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Technology Assessment | Environmental Health | Health Systems | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | North America